GE HealthCare to acquire SOFIE Biosciences, establishing a ‘final mile’ footprint for PET radiopharmaceutical supply in the U.S.
- Broadens GE HealthCare’s footprint in the U.S. radiopharmaceutical industry, drives patient access to F18 […]
FAP in Focus Symposium Showcases Further Advances in FAP Targeting
June 5, 2026 – Five years after its inception, SOFIE’s FAP symposium continues to bring […]
SOFIE Biosciences Announces First Patient Dosed in [18F]FAPI-74 Phase 3 Study for Pancreatic Cancer
- First dose at HOAG Health in FAPI-PRO trial for Pancreatic Ductal Adenocarcinoma
- A parallel […]
SOFIE drives U.S. manufacture of [18F]FAPI-74
Seven SOFIE radiopharmacies now produce the FAP-targeting radiopharmaceutical, as SOFIE launches Phase 3 clinical trials […]
SOFIE Biosciences Announces First Patient Dosed in [18F]FAPI-74 Phase 3 Study
- First dose at RadNet, in partnership with Helios Clinical and The Oncology Institute of […]
SOFIE activates FAPI-PRO, second [18F]FAPI-74 Phase 3 trial
FAPI-PRO is a GO!
SOFIE is proud to announce FAPI-PRO, our [18F]FAPI-74 Phase 3 study on […]
SOFIE activates FAPI-GO, first [18F]FAPI-74 Phase 3 trial
Another defining moment for SOFIE Biosciences!
Last Friday, November 14, 2025, FAPI-GO, SOFIE’s [18F]FAPI-74 Phase 3 […]
![SOFIE Biosciences Prepares Launch of Two [18F]FAPI-74 Phase 3 Studies, following successful FDA engagement](https://sofie.com/wp-content/uploads/2025/09/Graphic_EOP2-PR_News-Post.jpg)
SOFIE Biosciences Prepares Launch of Two [18F]FAPI-74 Phase 3 Studies, following successful FDA engagement
- Favorable End-of-Phase 2 meeting with U.S. FDA for [18F]FAPI-74 for GI cancers
- Primary and […]
SOFIE network expands production of 18F-FAPI-74
2024 Was a Banner Year for FAPI Tech Transfer!
Thanks to the diligent efforts of our […]
SOFIE and GE HealthCare SNMMI Symposium highlights FAP targeting
June 9, 2024 (Toronto, CA) – SNMMI annual meeting attendees had the opportunity to learn […]